Analysis of Brain Tumors Using Matrix Assisted Laser Desorption/Ionization Mass Spectrometry

Brain Diseases Clinical Trial

Official title:

Analysis of Brain Tumors Using Matrix Assisted Laser Desorption/Ionization Mass Spectrometry

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00592709
• Other study ID #: 030258
• Status: Completed
• Start date: May 2003
• Est. completion date: December 2012

Study information

• Verified date: February 2021
• Source: Vanderbilt University Medical Center
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

We are collecting brain tissue specimens and blood samples from patients at Vanderbilt University Medical Center who are undergoing intracranial surgery to remove brain tissue, including brain tumors, tissue from epilepsy surgery and brain tissue removed during surgery for other non-cancerous types of brain tissus. These specimens will then be studied using a novel microscopic laser-directed protein mass spectrometric analysis, looking for unique protein signatures.

Description:

We are collecting brain tissue specimens and blood samples from patients at Vanderbilt University Medical Center who are undergoing intracranial surgery to remove brain tissue, including brain tumors, tissue from epilepsy surgery and brain tissue removed during surgery for other non-cancerous types of brain tissus. These specimens will then be studied using a novel microscopic laser-directed protein mass spectrometric analysis. Data from different brain tissues including tumors of different histological sub-types will be analyzed for unique protein signatures. These protein signatures will then be statistically correlated with clinical data including time to tumor progression and response to therapy.

The goal of this study is to determine molecular patterns that will be more predictive of tumor behavior, thus leading to an improved understanding of the basic biology of these poorly understood cancers. This in turn, may lead to more refined therapies and improved outcomes.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 84
• Est. completion date: December 2012
• Est. primary completion date: December 2010
• Accepts healthy volunteers: No
• Gender: All
• Age group: 2 Years to 85 Years

Eligibility

Inclusion Criteria:

• A diagnosis of brain tumor or other non-cancerous tissue and are considered candidates fro a surgical procedure to biopsy or remove the brain tumor or other tissue type at Vanderbilt University Medical Center.

• Age 2 to 85

Exclusion Criteria:

• Patient or guardian that is unable to understand the informed consent process.

Related Conditions & MeSH terms

• Brain Diseases

Locations

Country	Name	City	State
United States	Vanderbilt University Medical Center, Department of Neurological Surgery	Nashville	Tennessee

Sponsors (1)

Lead Sponsor	Collaborator
Vanderbilt University Medical Center

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Measurement of proteomic signatures in brain tumor samples	measurement of proteomic signatures in brain tumor samples for unique protein signatures	immediately upon analysis of the sample